Navigating Contact Lens Innovation Amidst Market Volatility

The Cooper Companies, Inc. is a global medical device company operating through two wholly-owned subsidiaries: CooperVision and CooperSurgical. CooperVision manufactures and sells a comprehensive range of contact lenses, including daily disposable, monthly replacement, toric, and multifocal lenses, under brands such as MyDay, Biofinity, Avaira, and clariti. CooperSurgical focuses on fertility, women's health, and gynecology, offering products for assisted reproductive technology, prenatal genetic testing, and minimally invasive surgical procedures.

The company generates revenue through a diversified channel strategy: CooperVision sells to optical chains, independent eye care practitioners, and online retailers across 100+ countries, while CooperSurgical distributes through fertility clinics, hospitals, and specialty distributors. Approximately 70% of total revenue originates from outside the United States, providing geographic diversification.

With 195.03M shares outstanding and a public float of 193.68M shares, the company is widely held by institutional investors. Fiscal 2025 revenue was approximately $3.6B, with CooperVision contributing roughly 60% and CooperSurgical 40%. The company employs over 15,000 people worldwide and invests approximately 4-5% of annual revenue back into research and development.

• Near-Term (0-12 Months): The immediate focus centers on stabilizing CooperVision's market position amid aggressive competitive launches. Management expects mid-single-digit revenue growth in fiscal 2026, driven by continued expansion of MyDay in international markets and the ramp-up of the recently launched Avaira Vitality family in the United States. CooperSurgical is projected to grow 4-6% on the strength of its fertility franchise, particularly in the Asia-Pacific region where IVF adoption rates remain below Western averages.

• Medium-Term (1-3 Years): The company's growth algorithm relies on three pillars: (1) the global daily disposable lens market, expected to grow from $14B to $18B by 2029, where CooperVision holds roughly 18% share; (2) myopia management solutions, with the company's MiSight 1-day lens gaining regulatory approvals in additional countries; and (3) CooperSurgical's expansion into preimplantation genetic testing and non-invasive prenatal screening, a market projected to reach $5B by 2028. Management targets long-term revenue growth of 6-8% annually with operating margin expansion of 50-100 basis points per year.

Note: FY2025 figures are estimates based on current trading data; EPS shown is adjusted. Trailing GAAP EPS is $1.18 per live market data.

The financial trajectory reflects a temporary margin contraction in fiscal 2025 as the company absorbed higher raw material costs and increased promotional spending to defend market share. Revenue growth decelerated to approximately 2% as competitive pressures intensified in the U.S. contact lens market. However, the company's gross margin remains structurally sound at approximately 66%, supported by manufacturing scale and product mix shifts toward higher-margin daily disposables.

Looking forward, we project a return to mid-single-digit revenue growth as new product launches gain traction and international expansion continues. Operating margin is expected to recover to 19.8% by fiscal 2027 as promotional intensity normalizes and the company realizes operating leverage from its fixed manufacturing base. Free cash flow conversion remains strong at roughly 90% of adjusted net income, supporting the company's capacity for debt reduction and strategic investments.

The global contact lens market is valued at approximately $12B annually, with daily disposable lenses representing the fastest-growing segment at 6-8% annual growth. CooperVision holds the #2 position in this category with an estimated 18-20% global market share, behind Johnson & Johnson Vision but ahead of Alcon. The broader women's health market, where CooperSurgical competes, exceeds $30B globally with the fertility segment growing at 8-10% annually.

Competitive dynamics in contact lenses are intensifying as Alcon aggressively markets its Precision1 daily lens and J&J expands its Acuvue Oasys 1-Day portfolio. CooperVision differentiates through value-priced daily lenses (clariti) and its water-gradient technology in MyDay, which offers enhanced comfort. In toric and multifocal segments, the company's Biofinity family maintains strong practitioner loyalty, providing a defensive moat against share erosion.

In women's health, CooperSurgical competes with EMD Serono (fertility drugs), Illumina (genetic testing), and Hologic (surgical products), but maintains a unique position as the only major player offering both consumables and instrumentation across the full fertility treatment cycle. This integrated approach creates switching costs and cross-selling opportunities that support above-market growth.

Our valuation framework combines a discounted cash flow (DCF) analysis with comparable company multiples to triangulate a fair value range.

DCF Analysis: We model 10-year revenue growth of 5-7% annually, converging to a terminal growth rate of 3% (consistent with long-term GDP growth). Key assumptions include: operating margin expansion to 21% by 2030, an effective tax rate of 18%, and capital expenditures of 3% of revenue. Using a weighted average cost of capital (WACC) of 8.5%—reflecting the company's beta of 0.82, a 6% equity risk premium, and a 3.5% risk-free rate—we derive a present value of future cash flows that implies a fair value range of $75-$85 per share.

Note: Multiples based on current price of $62.80 and consensus NTM estimates.

The current price of $62.80 implies an EV/EBITDA multiple of approximately 18.5x, which is at a premium to medical device peers given the company's historically superior growth profile. However, the forward P/E of 53x appears stretched when compared to Alcon's 28x, reflecting the market's skepticism about near-term earnings recovery given the depressed trailing EPS of $1.18. Our DCF suggests the stock is undervalued at current levels, with material upside if management executes on its growth plan and margins recover as projected.

• Competitive Share Loss: Aggressive pricing and promotional activity from Alcon and J&J could erode CooperVision's market share in daily silicone hydrogel lenses, particularly in the U.S. where the company faces the most intense competition. A 200-basis-point share loss would reduce revenue by approximately $70M annually.

• Regulatory and Recall Exposure: As a medical device manufacturer, the company faces inherent product liability and regulatory risks. A recall in the contact lens or fertility product lines—similar to industry-wide events in recent years—could result in significant remediation costs, reputational damage, and temporary revenue disruption.

• FX and Geopolitical Volatility: With 70% of revenue derived internationally, currency fluctuations pose a meaningful earnings risk. A 5% appreciation of the U.S. dollar would reduce reported revenue by approximately $125M and EPS by roughly $0.15. Additionally, manufacturing concentration in Puerto Rico and the Philippines creates supply chain vulnerability to natural disasters or geopolitical disruptions.

• Integration and Execution Risk: The company's growth strategy relies on successful new product launches and potential acquisitions. Delays in regulatory approvals for myopia management products or missteps in integrating future acquisitions could impair growth expectations and pressure the stock's premium valuation.

• Elevated Valuation Risk: At 53x trailing EPS, the stock price embeds aggressive growth expectations. Any downward revision to fiscal 2026 guidance—whether from competitive pressures, FX headwinds, or operational setbacks—could trigger a de-rating toward peer multiples, implying additional downside of 20-30% from current levels.